SB 2221: USDA; TERMINAL ILLNESS; RIGHT-TO-TRY; INVESTIGATIVE DRUG OR BIOLOGICAL PRODUCT; ACCESS TO CARE
- Session Year: 2025-2026
- House: Senate
Current Status:
In Progress
(2026-01-26: Referred to HHS, CPN/JDC.)
Introduced
First Committee Review
First Chamber
Second Committee Review
Second Chamber
Final Decking
Enacted
Version:
Authorizes manufacturers of investigational drugs or biological products that are pending approval by the United States Food and Drug Administration to make the drugs or products available to terminally ill patients under certain conditions.